These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1157 related items for PubMed ID: 26573234

  • 1. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH.
    Oncotarget; 2016 Jan 19; 7(3):2401-16. PubMed ID: 26573234
    [Abstract] [Full Text] [Related]

  • 2. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z, Niu J, Cao Y, Pang X, Cui W, Zhang W, Li X.
    J Clin Pathol; 2020 Mar 19; 73(3):126-138. PubMed ID: 31615842
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N, Uner A, Benekli M, Barista I.
    Cancer; 2012 Sep 01; 118(17):4173-83. PubMed ID: 22213394
    [Abstract] [Full Text] [Related]

  • 4. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.
    McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.
    Haematologica; 2018 Nov 01; 103(11):1899-1907. PubMed ID: 29903764
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB.
    J Clin Oncol; 2012 Oct 01; 30(28):3460-7. PubMed ID: 22665537
    [Abstract] [Full Text] [Related]

  • 6. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX, Liu YH, Luo DL, Zhang F, Cheng Y, Luo XL, Xu J, Cheng J, Zhuang HG.
    PLoS One; 2014 Oct 01; 9(8):e104068. PubMed ID: 25090026
    [Abstract] [Full Text] [Related]

  • 7. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, German High-Grade Lymphoma Study Group.
    J Clin Oncol; 2017 Aug 01; 35(22):2515-2526. PubMed ID: 28525305
    [Abstract] [Full Text] [Related]

  • 8. Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.
    Ting CY, Chang KM, Kuan JW, Sathar J, Chew LP, Wong OJ, Yusuf Y, Wong L, Samsudin AT, Pana MNBM, Lee SK, Gopal NSR, Puri R, Ong TC, Bahari SK, Goh AS, Teoh CS.
    Int J Med Sci; 2019 Aug 01; 16(4):556-566. PubMed ID: 31171907
    [Abstract] [Full Text] [Related]

  • 9. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
    Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Møller MB, Wu L, Medeiros LJ, Young KH.
    Haematologica; 2013 Feb 01; 98(2):255-63. PubMed ID: 22929980
    [Abstract] [Full Text] [Related]

  • 10. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, Fenske TS, Jaso J, Medeiros LJ, Yang DT, Nabhan C.
    Cancer; 2016 Feb 15; 122(4):559-64. PubMed ID: 26565895
    [Abstract] [Full Text] [Related]

  • 11. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL, Liu YH, Zhang F, Xu FP, Yan LX, Chen J, Xu J, Luo XL, Zhuang HG.
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep 15; 42(9):584-8. PubMed ID: 24314242
    [Abstract] [Full Text] [Related]

  • 12. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD.
    J Clin Oncol; 2012 Oct 01; 30(28):3452-9. PubMed ID: 22851565
    [Abstract] [Full Text] [Related]

  • 13. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, German High-Grade Non-Hodgkin Lymphoma Study Group.
    Blood; 2013 Mar 21; 121(12):2253-63. PubMed ID: 23335369
    [Abstract] [Full Text] [Related]

  • 14. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ, Gang AO, Brown P, Pedersen M, Knudsen H, Nielsen SL, Poulsen T, Wirenfeldt Klausen T, Høgdall E, Nørgaard P.
    PLoS One; 2017 Mar 21; 12(10):e0186983. PubMed ID: 29088292
    [Abstract] [Full Text] [Related]

  • 15. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
    Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Ohshima K, Sone H, Takizawa J.
    Cancer Sci; 2016 Jun 21; 107(6):853-61. PubMed ID: 27027803
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S, Nong L, Wang W, Liang L, Zheng Y, Liu J, Li D, Li X, Zhang B, Li T.
    Diagn Pathol; 2019 Jul 17; 14(1):81. PubMed ID: 31315646
    [Abstract] [Full Text] [Related]

  • 17. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
    Xia Y, Zhang X.
    Acta Haematol; 2020 Jul 17; 143(6):520-528. PubMed ID: 32074595
    [Abstract] [Full Text] [Related]

  • 18. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP, Mihaljevic B, Jakovic L, Martinovic VC, Fekete MD, Andjelic B, Antic D, Bogdanovic A, Boricic N, Terzic T, Jelicic J, Milenkovic S.
    J BUON; 2015 Jul 17; 20(3):820-8. PubMed ID: 26214636
    [Abstract] [Full Text] [Related]

  • 19. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
    Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.
    J Clin Oncol; 2019 Dec 10; 37(35):3359-3368. PubMed ID: 31498031
    [Abstract] [Full Text] [Related]

  • 20. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, Sehn LH, Fu K, Aoun P, Greiner TC, Chan WC, Bierman PJ, Bociek RG, Armitage JO, Vose JM, Gascoyne RD, Weisenburger DD.
    Br J Haematol; 2014 May 10; 165(3):382-91. PubMed ID: 24506200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.